Web Analytics Made Easy - Statcounter

top of page

Multiple Myeloma Clinical Trials - @ PENN Medicine - Abramson Cancer Center

PENN Medicine - Abramson Cancer Center Myeloma trials

NCT05032820

NCT05032820

NCT04680468

NCT04680468

NCT05139225

NCT05139225

NCT05032820

NCT05032820

1/12

Multiple Myeloma Clinical Trials Currently Recruiting

NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

2021 (R) NCT05032820

Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial

2021 (R) NCT04771078

Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial

NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance

2020 (R) NCT04680468

Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance

NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

2019 (R) NCT04133636

Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2

NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

2019 (R) NCT04108195

Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC

2019 (R) NCT04071457

Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC

NCT04045028: Phase 1: Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma

2019 (R) NCT04045028

Phase 1: Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma

NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM

2017 (R) NCT03275103

Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM

NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM

2017 (R) NCT03215030

Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM

NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1

2017 (R) NCT03145181

Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1

NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM

2016 (R) NCT02899052

Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM

United States - Myeloma Clinical Trials | MCT Index (themyelomaclinicaltrials.com)

bottom of page